<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355550</url>
  </required_header>
  <id_info>
    <org_study_id>KET-06-003</org_study_id>
    <nct_id>NCT00355550</nct_id>
  </id_info>
  <brief_title>Tricaprilin In Age-Associated Memory Impairment</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Study of Tricaprilin (AC-1202) Administered For Ninety Days In Subjects With Age-Associated Memory Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerecin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerecin</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether tricaprilin, a compound that increases&#xD;
      energy availability in the brain, improves memory in older adults with &quot;normal&quot; loss of&#xD;
      memory abilities since early adult life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One physiological hallmark of aging in mammals is a decreased uptake and metabolism of&#xD;
      glucose within the brain. The impaired glucose metabolism in the brain may contribute or&#xD;
      exacerbate the cognitive deficits observed during normal aging. Facilitation of memory in&#xD;
      elderly individuals occurs when glucose levels are elevated by the administration of&#xD;
      carbohydrate. However, such a treatment poses challenges since elevated blood glucose levels&#xD;
      are difficult to maintain and must be within a relatively narrow window, as excessive&#xD;
      hyperglycemia is associated with cognitive impairments. The purpose of this study is to&#xD;
      explore whether increasing levels of other substrates for the brain improves cognitive&#xD;
      functioning in normal aged individuals with memory disorders.&#xD;
&#xD;
      Study participants will be 120 men and women aged 50-85 who have been diagnosed as having&#xD;
      Age-Associated Memory Impairment (AAMI). During the double-blind period of the protocol, 60&#xD;
      participants will receive tricaprilin and 60 participants will receive a matching placebo.&#xD;
      Tricaprilin or the matching placebo will be administered once a day for ninety days by mixing&#xD;
      powder in 8 ounces of a liquid. Each participant will be seen six (6) times: at Screening;&#xD;
      Baseline; treatment days Days 30, 60, 90; and 14 days after the conclusion of treatment (Day&#xD;
      104).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Psychologix and Cogscreen Test Batteries, RAVLT (Rey Auditory Verbal Learning Test)</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with treatment related adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>AE incidence rate per treatment group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-reported memory improvement</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Age-Associated Memory Impairment</condition>
  <arm_group>
    <arm_group_label>AC-1202</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tricaprilin formulation, once daily. Administered orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo to AC-1202</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo formulation, once daily. Administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tricaprilin</intervention_name>
    <description>Powder formulation will be mixed in a liquid (approximately 8 oz).</description>
    <arm_group_label>AC-1202</arm_group_label>
    <other_name>AC-1202</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powder formulation will be mixed in a liquid (approximately 8 oz).</description>
    <arm_group_label>Matching Placebo to AC-1202</arm_group_label>
    <other_name>Matching placebo to AC-1202</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Complaints that memory has declined since young adult life&#xD;
&#xD;
          -  Scores on standardized tests that are at least one standard deviation below the mean&#xD;
             score of young adults&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia, including Alzheimer's disease and Mild Cognitive Impairment (MCI)&#xD;
&#xD;
          -  Drugs that impair cognition&#xD;
&#xD;
          -  Psychiatric conditions that may impair cognition (e.g.,depression etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Henderson, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cerecin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas H. Crook III, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychologix, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Hochadel, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>Advanced Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research-DeLand</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anchor Research Center</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renstar Medical Research</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Center</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004 Mar;25(3):311-4.</citation>
    <PMID>15123336</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 20, 2006</study_first_submitted>
  <study_first_submitted_qc>July 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2006</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Cognition disorders</keyword>
  <keyword>nutritional supplement</keyword>
  <keyword>dietary supplement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memory Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

